Skip to main content

Multi-Market Submission Strategy

Manufacturers targeting multiple major markets face the challenge of meeting different regulatory requirements efficiently. A well-planned multi-market strategy can reduce duplication and speed overall time to global market.

Common data package approach​

Many regulatory submissions across major markets require similar technical data. A common technical file can be tailored for each jurisdiction:

Data elementFDA 510(k)/PMAEU MDRTGAHealth CanadaHSA
Device description✓✓✓✓✓
Risk management (ISO 14971)✓✓✓✓✓
Biocompatibility (ISO 10993)✓✓✓✓✓
Electrical safety (IEC 60601)✓✓✓✓✓
Software (IEC 62304)✓✓✓✓✓
Clinical evidence✓ (varies)✓ (mandatory)✓ (varies)✓ (varies)✓ (varies)
QMS certificate (ISO 13485)✓ (via QMSR)✓✓✓✓

Strategic sequencing options​

FDA-first strategy​

Advantages:

  • FDA clearance/PMA is accepted as reference in Singapore (abridged route) and Australia (comparable overseas regulator)
  • US clinical data collected under IDE is often usable for other markets
  • FDA's rigorous review provides commercial credibility globally

Disadvantages:

  • FDA review timelines can be longer than EU Notified Body for some device types
  • FDA clinical data requirements may differ from EU/other expectations

CE-first strategy

Advantages: CE marking review timelines by Notified Bodies are often shorter than FDA review for Class IIa/IIb devices, typically 3-6 months versus 6-12 months or longer for FDA 510(k) review; faster market access in EU.

Disadvantages:

  • CE marking is not accepted by FDA — separate US submission required
  • EU MDR requirements (mandatory clinical data, PMCF) are increasingly burdensome

Parallel strategy​

For most manufacturers targeting 3+ markets, parallel submissions (filing in multiple jurisdictions simultaneously) is optimal:

  • Prepare a common technical file
  • Tailor the covering document and format for each jurisdiction
  • Manage responses to regulatory questions across markets simultaneously

Key reliance opportunities​

Target marketWhat FDA clearance enables
Australia (TGA)Comparable overseas regulator pathway — can submit an abbreviated application relying on FDA decision
Singapore (HSA)Abridged route — accepts FDA 510(k) or PMA as primary reference
Canada (Health Canada)Reference device concept for Class II (limited)
EUNo reliance on FDA — full MDR/IVDR conformity required independently

Official resources​